Meet the Expert
Session
24 - 25 September 2015,
NH Milano 2,
Milan, Italy
ChairDr. Anita Hill

Anita Hill, MBChB (Hons), MRCP, FRCPath, PhD

Anita Hill, MBChB (Hons), MRCP, FRCPath, PhD Department of Haematology, St. James’ University Hospital, Leeds, UK

Anita Hill is a Consultant Haematologist for Leeds Teaching Hospitals NHS Trust, UK and also Honorary Senior Lecturer at the University of Leeds. Additionally, she works within the nationally commissioned National PNH Service based in Leeds. Prior to this, Dr. Hill worked as a Consultant Haematologist for Bradford Teaching Hospitals NHS Foundation Trust, where she was the Lead for clinical trials and research. Dr. Hill received her medical degree with distinctions and honours from the University of Sheffield, UK. She did her post-graduate training at Sheffield Teaching Hospitals NHS Trust, St George’s Hospital, London and the Royal Marsden Hospital, London. Dr. Hill went on to specialise in haematology at Leeds Teaching Hospitals NHS Trust. She was awarded her PhD for exploring the role of complement and nitric oxide in the pathophysiology of PNH and other haemolytic anaemias.

Dr. Hill has published extensively in peer-reviewed journals. She is actively involved in the PNH Global Registry, as well as a member of the Royal College of Pathologists, the British Society of Haematology and the International PNH Interest Group. She has served as an elected member of the North of England Regional Council, Royal College of Pathologists and is a committee member for the UK Red Cell Specialist Interest Group.

T. Sakari Jokiranta, MD, PhD

T. Sakari Jokiranta, MD, PhD Department of Bacteriology and Immunology, Haartman Institute,
University of Helsinki, Helsinki, Finland

Sakari Jokiranta is a Senior Lecturer and Principal Investigator leading a research group focused on atypical haemolytic uraemic syndrome (aHUS) at the Haartman Institute at the University of Helsinki. He graduated in medicine from the University of Helsinki, Finland. Prior to graduation, he began research on complement activation under the supervision of Prof. Seppo Meri. For his PhD studies Sakari Jokiranta visited the Bernhard Nocht Institute in Hamburg, Germany. He then worked as a post-doctoral researcher and Senior Registrar at the Flinders Medical Centre in Adelaide, Australia. Sakari Jokiranta obtained Certified Specialist status in clinical microbiology and immunology in 2001 and became Adjunct Professor in 2006 at the University of Helsinki.

Prof. Jokiranta is author of over 70 articles in peer-reviewed journals.The most important of his publications deal either with discrimination between pathogens and self-cells by the complement system, or the molecular pathogenesis of aHUS.

Richard Kelly, MD

Austin Kulasekararaj, MD King’s College Hospital and King’s College London, UK

Austin Kulasekararaj is a Consultant Haematologist working at King’s College Hospital and King’s College London and is also working within the English National PNH service. He did his graduate and post-graduate training in internal medicine in India. He subsequently completed his medical and specialist haematology training at King’s College Hospital, London.

His special interest is in bone marrow failure syndromes and he works closely with Prof. Ghulam Mufti and Prof. Judith Marsh. He is currently completing his PhD in microRNA and molecular pathogenesis of myelodysplastic syndromes (MDS).

He has contributed to key publications in the field of molecular and immunological aspects of bone marrow failures, especially MDS. He is a Leukaemia and Lymphoma Research foundation (LLR) and British Society of Haematology (BSH) senior clinical research fellow.

Dr. Kulasekararaj is a member of BSH and is also a member of the EBMT Severe Aplastic Anaemia Working Party (SAAWP).

Dr Talha Munir

Dr Talha Munir MBBS, MRCP (UK), FRCPath (UK) St James’s University Hospital, Leeds, UK

Dr Tal Munir graduated from King Edward Medical College, Lahore Pakistan in 2002. He finished his initial training in Pakistan and has been working for the NHS since 2004. Dr Munir’s haematology training was primarily based in Nottingham from 2008—2012. In 2014 he joined the PNH National Service in Leeds, where service commitments include the management of patients with aplastic anaemia and PNH. He has a special interest in the development of PNH service provision in the UK through the PNH National Service. He regularly takes part in the management of patients with PNH and contributes towards increasing awareness of the PNH National Service through education of colleagues in haematology and other specialities. Dr Munir has a keen interest in PNH research activities as well as the development of a PNH trial portfolio in the UK.

Dr Munir started his PhD in 2012 in the assessment of the mechanism of action of novel targeted therapies for chronic lymphocytic leukaemia (CLL). He has a clinical and research interest in CLL, particularly in the mechanism of action of novel targeted therapies. He is sub-investigator for National Cancer Research Institute (NCRI) CLL phase II and III clinical trials in the UK. Multiple NCRI and non-NCRI trials are conducted at Leeds, UK, resulting in an impressive trial portfolio.

In addition to his clinical commitments, Dr Munir is in the process of finishing his PhD in CLL. He has a special interest in the management of rare adult histiocytic disorders, especially Langerhans’ cell histiocytosis and Erdheim Chester disease.